Therapeutic effect of Bacillus sp. DU-106 lysate on 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice

Abstract:

[Background] Our research team have discovered that Bacillus sp. DU-106 has good health benefits in previous studies. However, the conclusion is based on the studies of living bacteria and the studies of inactivated bacteria remain to be carried out. [Objective] To investigate the effect and mechanism of Bacillus sp. DU-106 lysate in the treatment of atopic dermatitis. [Methods] Pathological observation and immunohistochemistry were employed to study the therapeutic effect of Bacillus sp. DU-106 lysate on the mouse model of 2,4-dinitrofluorobenzene-induced atopic dermatitis. The expression levels of the proteins involved in the nuclear factor kappa-B (NF-κB) signaling pathway were determined to reveal the mechanism. [Results] Bacillus sp. DU-106 lysate alleviated the pathological changes, reduced the infiltration of mast cells, and lowered the levels of immunoglobulin E, tumor necrosis factor-α (TNF-α), and interferon-γ (P<0.05) in the model mice. Furthermore, Bacillus sp. DU-106 lysate down-regulated the expression levels and inhibited the phosphorylation of TNF-α, inhibitory kappa B kinase α (IKKα), and NF-κB in the NF-κB signaling pathway in the model mice. [Conclusion] Bacillus sp. DU-106 lysate can be used as a probiotic with therapeutic effects on atopic dermatitis.